Ionis Pharmaceuticals, Inc. reported significant financial growth in its latest quarterly results, with total revenue reaching $246.1 million for the three months ended March 31, 2026, compared to $131.6 million for the same period in 2025. This 87% increase was primarily driven by strong commercial revenue from product sales, particularly from the recently launched medicines TRYNGOLZA and DAWNZERA, which generated $27.1 million and $15.9 million in sales, respectively. Additionally, research and development revenue surged to $138.3 million, bolstered by milestone payments from collaborations with partners such as GSK and Roche.
The company experienced a net loss of $92.5 million, a notable improvement from the $146.9 million loss reported in the prior year. This reduction in losses was attributed to increased revenue and a more efficient cost structure, despite total operating expenses rising to $363.5 million from $278.5 million year-over-year. The increase in expenses was largely due to heightened selling, general, and administrative costs associated with the commercialization of new products and ongoing development activities.
Ionis has made strategic advancements in its product portfolio, with the successful launch of two new medicines and ongoing development of several others. The company is positioned to independently launch additional products, including olezarsen for severe hypertriglyceridemia and zilganersen for Alexander disease, both anticipated in 2026, pending regulatory approvals. The company’s collaboration with AstraZeneca for the development of WAINUA has also progressed, with AstraZeneca taking on a larger share of development costs moving forward.
Operationally, Ionis has expanded its market presence, with significant sales contributions from its marketed medicines. The company reported a total of 165.9 million shares outstanding as of March 31, 2026, reflecting an increase in employee stock plans. The company’s cash and cash equivalents stood at $173.4 million, down from $372.3 million at the end of 2025, primarily due to cash used in operating activities. Looking ahead, Ionis remains optimistic about its growth trajectory, driven by its innovative pipeline and the anticipated success of its commercial launches, while also acknowledging the challenges posed by market competition and regulatory environments.
About IONIS PHARMACEUTICALS INC
Ionis Pharmaceuticals is a biotech company specializing in RNA-targeted therapeutics. It develops and commercializes medicines for serious diseases across neurology, cardiology, and rare genetic disorders. Its core products include antisense and siRNA medicines, with a focus on genetic and neurodegenerative conditions. The company partners with global pharma firms, leveraging innovative technology to deliver life-changing treatments and generate revenue through product sales, royalties, and milestone payments.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.